Contribution of TF expressed by hematopoietic and nonhematopoietic cells to the activation of coagulation. (A) Effect of cH36 (50 μg/mL) or IgG (50 μg/mL) control antibody on LPS-induced plasma TAT levels in HTF mice (mean ± SEM for IgG, IgG/LPS and cH36/LPS groups were 2.6 ± 0.9, 34.2 ± 6.2 and 5.3 ± 3.4 ng/mL, respectively) 8 hours after LPS injection. (B) Effect of cH36 (50 μg/mL) or IgG (50 μg/mL) control antibody on LPS-induced plasma TAT levels in WT mice (mean ± SEM for IgG, IgG/LPS and cH36/LPS groups were 3.3 ± 1.7, 38.9 ± 4.2 and 36.1 ± 6.6 ng/mL, respectively) 8 hours after LPS injection (n = 3 for all treatment conditions). *Statistically significant difference (P < .05) between IgG- and IgG/LPS-treated group. **Statistically significant difference (P < .05) between IgG/LPS- and cH36/LPS-treated group. (C) PCR analysis of DNA isolated from blood cells from mice that underwent bone marrow transplantation to demonstrate reconstitution of the donor mice with recipient bone marrow 6 weeks after the transplantation. (D) Plasma TAT levels were analyzed in WT mice transplanted with bone marrow from HTF mice after treatment with IgG (n = 13; mean ± SEM 55.9 ± 5.7 ng/mL) or cH36 (n = 13; mean ± SEM 29.6 ± 3.6 ng/mL) 8 hours after LPS injection. *P < .05. (E) Plasma TAT levels were analyzed 8 hours after LPS injection in HTF mice transplanted with WT bone marrow after treatment with IgG (n = 12; mean ± SEM 46.6 ± 6.5 ng/mL) or cH36 (n = 13; mean ± SEM 28.5 ± 4.1 ng/mL;). *P < .001.